Drug Approval | April 24, 2023
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Bourgoin early development hub broadens offerings for oral solid dose formulations
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Subscribe To Our Newsletter & Stay Updated
